S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Sponsor: Eastern Cooperative Oncology Group
Listed as NCT00003590, this PHASE2 trial focuses on Adult Meningioma and remains completed. Sponsored by Eastern Cooperative Oncology Group, it has been updated 9 times since 1998, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — May 2023 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Nov 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aberdeen, United States, American Fork, United States, Anderson, United States, Annapolis, United States, Auburn, United States, Aurora, United States, Baltimore, United States, Baton Rouge, United States, Billings, United States, Bloomington, United States and 88 more location s